BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 15473989)

  • 1. Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells.
    Presgraves SP; Borwege S; Millan MJ; Joyce JN
    Exp Neurol; 2004 Nov; 190(1):157-70. PubMed ID: 15473989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ; Di Cara B; Hill M; Jackson M; Joyce JN; Brotchie J; McGuire S; Crossman A; Smith L; Jenner P; Gobert A; Peglion JL; Brocco M
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole.
    Joyce JN; Presgraves S; Renish L; Borwege S; Osredkar T; Hagner D; Replogle M; PazSoldan M; Millan MJ
    Exp Neurol; 2003 Nov; 184(1):393-407. PubMed ID: 14637109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pramipexole has astrocyte-mediated neuroprotective effects against lactacystin toxicity.
    Imamura K; Takeshima T; Nakaso K; Ito S; Nakashima K
    Neurosci Lett; 2008 Aug; 440(2):97-102. PubMed ID: 18555604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons.
    Du F; Li R; Huang Y; Li X; Le W
    Eur J Neurosci; 2005 Nov; 22(10):2422-30. PubMed ID: 16307585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: III. Actions in models of potential antidepressive and anxiolytic activity in comparison with ropinirole.
    Millan MJ; Brocco M; Papp M; Serres F; La Rochelle CD; Sharp T; Peglion JL; Dekeyne A
    J Pharmacol Exp Ther; 2004 Jun; 309(3):936-50. PubMed ID: 14978196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole.
    Millan MJ; Cussac D; Gobert A; Lejeune F; Rivet JM; Mannoury La Cour C; Newman-Tancredi A; Peglion JL
    J Pharmacol Exp Ther; 2004 Jun; 309(3):903-20. PubMed ID: 14978194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Both the antioxidant and D3 agonist actions of pramipexole mediate its neuroprotective actions in mesencephalic cultures.
    Ling ZD; Robie HC; Tong CW; Carvey PM
    J Pharmacol Exp Ther; 1999 Apr; 289(1):202-10. PubMed ID: 10087005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.
    Millan MJ; Iob L; Péglion JL; Dekeyne A
    Psychopharmacology (Berl); 2007 Apr; 191(3):767-82. PubMed ID: 17047933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells.
    Kitamura Y; Kosaka T; Kakimura JI; Matsuoka Y; Kohno Y; Nomura Y; Taniguchi T
    Mol Pharmacol; 1998 Dec; 54(6):1046-54. PubMed ID: 9855633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole.
    Maggio R; Scarselli M; Novi F; Millan MJ; Corsini GU
    J Neurochem; 2003 Nov; 87(3):631-41. PubMed ID: 14535946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms.
    Gu M; Iravani MM; Cooper JM; King D; Jenner P; Schapira AH
    J Neurochem; 2004 Dec; 91(5):1075-81. PubMed ID: 15569251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of organotypic ventral mesencephalic cultures from embryonic mice and protection against MPP toxicity by GDNF.
    Jakobsen B; Gramsbergen JB; Møller Dall A; Rosenblad C; Zimmer J
    Eur J Neurosci; 2005 Jun; 21(11):2939-48. PubMed ID: 15978005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct effects of pramipexole on the proliferation of adult mouse sub-ventricular zone-derived cells and the appearance of a neuronal phenotype.
    Merlo S; Canonico PL; Sortino MA
    Neuropharmacology; 2011 May; 60(6):892-900. PubMed ID: 21272591
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine protects dopaminergic neurons from levodopa-induced toxicity by stimulating D(2)receptors.
    Takashima H; Tsujihata M; Kishikawa M; Freed WJ
    Exp Neurol; 1999 Sep; 159(1):98-104. PubMed ID: 10486178
    [TBL] [Abstract][Full Text] [Related]  

  • 16. S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.
    Millan MJ; Gobert A; Newman-Tancredi A; Lejeune F; Cussac D; Rivet JM; Audinot V; Dubuffet T; Lavielle G
    J Pharmacol Exp Ther; 2000 Jun; 293(3):1048-62. PubMed ID: 10869410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiparkinson concentrations of pramipexole and PHNO occupy dopamine D2(high) and D3(high) receptors.
    Seeman P; Ko F; Willeit M; McCormick P; Ginovart N
    Synapse; 2005 Nov; 58(2):122-8. PubMed ID: 16088951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists.
    Presgraves SP; Ahmed T; Borwege S; Joyce JN
    Neurotox Res; 2004; 5(8):579-98. PubMed ID: 15111235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The excitoprotective effect of N-methyl-D-aspartate receptors is mediated by a brain-derived neurotrophic factor autocrine loop in cultured hippocampal neurons.
    Jiang X; Tian F; Mearow K; Okagaki P; Lipsky RH; Marini AM
    J Neurochem; 2005 Aug; 94(3):713-22. PubMed ID: 16000165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP; Ravenscroft P; McGuire SG; Brotchie JM; Crossman AR; Rochat C; Millan MJ
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.